These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17854239)

  • 1. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder.
    Dunayevich E; Ascher-Svanum H; Zhao F; Jacobson JG; Phillips GA; Dellva MA; Green AI
    J Clin Psychiatry; 2007 Aug; 68(8):1163-71. PubMed ID: 17854239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
    Citrome L; Yang R; Glue P; Karayal ON
    Schizophr Res; 2009 Jun; 111(1-3):39-45. PubMed ID: 19375893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
    Perkins DO; Gu H; Weiden PJ; McEvoy JP; Hamer RM; Lieberman JA;
    J Clin Psychiatry; 2008 Jan; 69(1):106-13. PubMed ID: 18312044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
    Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.
    Lindenmayer JP; Liu-Seifert H; Kulkarni PM; Kinon BJ; Stauffer V; Edwards SE; Chen L; Adams DH; Ascher-Svanum H; Buckley PF; Citrome L; Volavka J
    J Clin Psychiatry; 2009 Jul; 70(7):990-6. PubMed ID: 19497244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
    McEvoy JP; Citrome L; Hernandez D; Cucchiaro J; Hsu J; Pikalov A; Loebel A
    J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
    Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
    J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
    Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
    J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
    Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects.
    Emsley R; Chiliza B; Asmal L; Kilian S; Riaan Olivier M; Phahladira L; Ojagbemi A; Scheffler F; Carr J; Kidd M; Dazzan P
    Schizophr Res; 2017 Oct; 188():144-150. PubMed ID: 28130002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial.
    Takeuchi H; Lee J; Fervaha G; Foussias G; Agid O; Remington G
    J Clin Psychiatry; 2017 Feb; 78(2):223-228. PubMed ID: 28234436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.
    Ciapparelli A; Dell'Osso L; Bandettini di Poggio A; Carmassi C; Cecconi D; Fenzi M; Chiavacci MC; Bottai M; Ramacciotti CE; Cassano GB
    J Clin Psychiatry; 2003 Apr; 64(4):451-8. PubMed ID: 12716249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.